Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer
Just shy of two decades, the name of Erytech Pharma — and its mission of using red blood cells to deliver drugs for rare cancers and orphan diseases — will soon become biotech history.
The company has been searching for strategic alternatives since its lead drug flunked a Phase III pancreatic cancer trial in 2021. And it finally found the perfect match in fellow French drugmaker Pherecydes, which is focused on developing treatments against resistant bacterial infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.